MX2010003762A - Vacuna preventiva contra vih a base de anticuerpos especificos contra vih. - Google Patents

Vacuna preventiva contra vih a base de anticuerpos especificos contra vih.

Info

Publication number
MX2010003762A
MX2010003762A MX2010003762A MX2010003762A MX2010003762A MX 2010003762 A MX2010003762 A MX 2010003762A MX 2010003762 A MX2010003762 A MX 2010003762A MX 2010003762 A MX2010003762 A MX 2010003762A MX 2010003762 A MX2010003762 A MX 2010003762A
Authority
MX
Mexico
Prior art keywords
hiv
present
specific antibodies
peptides
polypeptides
Prior art date
Application number
MX2010003762A
Other languages
English (en)
Spanish (es)
Inventor
Elena Yu Filinova
Original Assignee
Technologie Integrale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technologie Integrale Ltd filed Critical Technologie Integrale Ltd
Publication of MX2010003762A publication Critical patent/MX2010003762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010003762A 2007-10-09 2008-10-09 Vacuna preventiva contra vih a base de anticuerpos especificos contra vih. MX2010003762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97853607P 2007-10-09 2007-10-09
PCT/EP2008/008544 WO2009046984A1 (en) 2007-10-09 2008-10-09 Hiv preventive vaccine based on hiv specific antibodies

Publications (1)

Publication Number Publication Date
MX2010003762A true MX2010003762A (es) 2010-09-10

Family

ID=40342551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003762A MX2010003762A (es) 2007-10-09 2008-10-09 Vacuna preventiva contra vih a base de anticuerpos especificos contra vih.

Country Status (12)

Country Link
US (1) US20100215695A1 (https=)
EP (1) EP2205736B1 (https=)
JP (1) JP2010540674A (https=)
KR (1) KR20100098597A (https=)
CN (1) CN101970659A (https=)
AU (1) AU2008309940B2 (https=)
BR (1) BRPI0818354A2 (https=)
CA (1) CA2701948A1 (https=)
MX (1) MX2010003762A (https=)
RU (1) RU2505604C2 (https=)
WO (1) WO2009046984A1 (https=)
ZA (1) ZA201002445B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422618A1 (en) * 2010-08-27 2012-02-29 Technologie Integrale Ltd. Animal model for the evaluation of the efficacy of an HIV vaccine
CN102190726B (zh) * 2011-03-30 2013-03-27 中国医学科学院病原生物学研究所 一种人源HIV抗体的Fab片段及其编码基因与应用
CN102212133B (zh) * 2011-03-30 2013-01-16 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
HK1200359A1 (zh) * 2011-09-17 2015-08-07 源道隆（苏州）医学科技有限公司 任意三个或以上氨基酸残基构成的多肽表位及其相关抗体的诱导
US10660951B2 (en) 2012-09-17 2020-05-26 Zhiwei Allen Wu Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
EP2745845A1 (en) * 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
RU2600031C2 (ru) * 2014-11-11 2016-10-20 Публичное акционерное общество "Фармсинтез" Лекарственная форма специфического иммунобиологического лекарственного средства для лечения и профилактики вич инфекции и способ ее получения
ES2959642T3 (es) * 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
EP3464348A4 (en) * 2016-05-25 2020-01-22 University Of Maryland, Baltimore METHOD FOR PRODUCING ACTIVE ANTIBODIES FROM BIOLOGICAL LIQUIDS
CN106800603B (zh) * 2017-01-24 2020-07-28 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法
EP3641806A4 (en) 2017-06-22 2021-06-23 University of Maryland, Baltimore BROAD NEUTRALIZING ANTIBODIES AGAINST HIV
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
IT202100004172A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Nuova composizione
IT202100004160A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Cellula ospite di leishmania

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV

Also Published As

Publication number Publication date
RU2505604C2 (ru) 2014-01-27
CA2701948A1 (en) 2009-04-16
US20100215695A1 (en) 2010-08-26
BRPI0818354A2 (pt) 2017-05-16
KR20100098597A (ko) 2010-09-08
EP2205736A1 (en) 2010-07-14
WO2009046984A1 (en) 2009-04-16
EP2205736B1 (en) 2014-04-02
AU2008309940A1 (en) 2009-04-16
AU2008309940B2 (en) 2013-11-14
JP2010540674A (ja) 2010-12-24
ZA201002445B (en) 2011-03-30
CN101970659A (zh) 2011-02-09
RU2010116849A (ru) 2011-11-20

Similar Documents

Publication Publication Date Title
MX2010003762A (es) Vacuna preventiva contra vih a base de anticuerpos especificos contra vih.
MX2012003538A (es) Cuantificacion multiple de proteinas recombinantes individuales en una mezcla mediante peptidos distintivos y espectrometria de masas.
WO2010009346A3 (en) Hiv vaccine based on targeting maximized gag and nef to dendritic cells
WO2008063331A3 (en) Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
TW200621806A (en) Vaccine
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
MX2014004214A (es) Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
WO2012046061A3 (en) Clostridium difficile antigens
IN2012DN02368A (https=)
WO2017079479A8 (en) Neutralizing antibodies to hiv-1 gp41 and their use
IN2009CN03372A (https=)
CA2837395C (en) Immunogenic composition comprising clostridium difficile toxin a and toxin b fusion protein
WO2011153400A3 (en) Nasal immunization
WO2009099777A3 (en) Chimeric hiv fusion proteins as vaccines
EP2293079A3 (en) Use of precursors of enkephalins and/or their fragments in medical diagnostics
Aparicio et al. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
WO2021252406A3 (en) Method for selecting antibody fragments, recombinant antibodies produced therefrom, and uses thereof
Wang et al. Comprehensive characterization of reference standard lots of HIV-1 subtype C Gp120 proteins for clinical trials in Southern African regions
EP2496608A4 (en) FUSION PROTEIN FOR THE SPECIFIC BINDING OF CONSTANT ANTIBODY REGIONS, PREPARATION THEREOF, AND METHOD FOR THE ANTIBODY INSULATION THEREWITH
WO2009129521A3 (en) Immunodominant mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization
WO2020047263A3 (en) Sequential immunization strategies to guide the maturation of antibodies against human immmunodeficiency virus
MX2023007583A (es) Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.
IN2012DN00250A (https=)
WO2007127290A3 (en) Method for producing viral vaccine and therapeutic peptide antigens

Legal Events

Date Code Title Description
FG Grant or registration